form8-k_090507.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
________________________________________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of
report (Date of earliest event reported): August 30, 2007
CYTOGEN
CORPORATION
________________________________________
(Exact
Name of Registrant as Specified in Charter)
|
|
|
|
|
(State
or Other Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification No.)
|
650
College Road East, CN 5308, Suite 3100, Princeton,
NJ
|
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (609) 750-8200
(Former
Name or Former Address, if Changed Since Last Report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
1.01 Entry
into a Material Definitive Agreement.
On
August
30, 2007, Cytogen Corporation (“Cytogen”) and InPharma AS (“InPharma”) executed
an amendment to the Product License and Assignment Agreement dated as of October
11, 2006 (the “License Agreement”) between the parties. Under
the License Agreement, InPharma granted Cytogen exclusive rights for
CAPHOSOL® in
North America. The License Agreement also provides Cytogen with the
option to acquire the rights to CAPHOSOL for the European and Asian
markets.
Under
the
amendment to the License Agreement, Cytogen and InPharma restructured the
amounts payable by Cytogen in connection with the exercise of the option for
European marketing rights. Cytogen currently is seeking a strategic
partner to market CAPHOSOL in Europe.
CAPHOSOL
is an advanced electrolyte solution for the treatment of oral mucositis caused
by radiation or high dose chemotherapy and dry mouth that is approved in the
U.S. as a prescription medical device. Cytogen introduced CAPHOSOL to
the U.S market in March 2007.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
CYTOGEN
CORPORATION
|
|
|
|
|
By:
|
|
|
|
Michael
D. Becker
|
|
|
President
and Chief Executive Officer
|
Dated: September
5, 2007